Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-95251 + rituximab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy of **CC-95251** (a monoclonal antibody targeting *signal regulatory protein alpha*, or SIRPα) and **rituximab** (an anti-CD20 monoclonal antibody). CC-95251 disrupts the SIRPα/CD47 pathway, enabling macrophage-mediated phagocytosis of cancer cells, while rituximab targets CD20-positive B-cells, inducing cytotoxicity by complement-dependent and antibody-dependent cellular mechanisms. The combination is under investigation for enhanced anti-tumor activity and improved resistance mechanism modulation, particularly in relapsed/refractory non-Hodgkin lymphoma and advanced solid/hematologic cancers. The combination is being evaluated in multicenter, open-label, Phase 1 clinical trials with IV administration[1][4][7][8][9].
- Brand names
- CC-95251 + rituximab
- Other names
- CC-95251 plus rituximabCC95251 plus rituximabCC 95251 plus rituximabCC-95251 in combination with rituximabCC95251 in combination with rituximabCC 95251 in combination with rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on CC-95251 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-95251 + rituximab.